We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Rhinomed Announces European Launch of Revolutionary New Swab for Testing Children for Respiratory Diseases

By LabMedica International staff writers
Posted on 15 Nov 2022
Print article
Image: Rhinoswab Junior is the happy way to swab children for respiratory viruses (Photo courtesy of Rhinomed)
Image: Rhinoswab Junior is the happy way to swab children for respiratory viruses (Photo courtesy of Rhinomed)

Rhinomed Limited (Cremorne, VIC, Australia) has launched the world’s most child-friendly respiratory swab in Europe at MEDICA 2022 in Dusseldorf, Germany. Rhinoswab Junior is the first nasal swab developed specifically for children. Its unique design addresses one of the pandemics' major challenges − testing reluctance − created by the fear, anxiety and discomfort associated with traditional combined throat and nose swabs. Rhinomed’s presence at MEDICA 2022 is the company’s first appearance in Europe as it seeks to bring this exciting new technology to market.

Rhinomed has developed the novel Rhinoswab Junior nasal swab designed specifically for children. The Rhinoswab Junior comfortably sits inside the nose and captures a significantly larger yield than standard nasal swabs. Its unique and engaging design removes the fear children experience with existing swabs. It can easily be integrated into existing rapid antigen and PCR tests for a range of respiratory viruses including SARS-CoV-2, RSV, Influenza, etc.

In a clinical trial led by the Murdoch Children’s Research Institute, leading pediatricians compared the current combined nose and throat swabs and saliva collection methods to Rhinoswab Junior. The trial demonstrated that Rhinoswab Junior is the best method for collecting samples from children when considering comfort, consistency, accuracy and efficacy. A National Child Health Poll identified that 74% of parents were reluctant to bring their children in for COVID-19 testing because of the potential trauma and pain of sampling, with up to 30% unlikely to test their children at all. The results of this new trial confirm that Rhinoswab Junior provides a child friendly, more comfortable alternative that addresses these concerns. 88% of children preferred Rhinoswab Junior compared to the standard swab, and it was the preferred method of sample collection for their next test. Rhinoswab Junior’s unique design also means children can collect their own samples, and parents and carers are more likely to ensure children are tested.

These results build on a previous Murdoch Children’s study of 249 hospital samples that concluded that the Rhinoswab Junior is clinically equivalent to a standard combined nose and throat swab, yet preferred by eight out of 10 children and preferred by parents and nursing staff. The trial provided clear compelling evidence of clinical efficacy. Rhinoswab Junior demonstrated significantly more sensitivity than saliva and was able to detect more cases of SARS-CoV-2. The Rhinoswab Junior detected 45 cases when compared to the combined throat and nasal swab which detected 44 SARS-CoV-2 cases, while saliva samples detected just 39 cases. For the first time, clinicians can improve testing uptake and rely on an anterior nares swab without any statistically significant loss in sensitivity.

In the trial, samples were self-collected by 53 children aged 4-18 years, with results demonstrating that Rhinoswab Junior is readily used by children to self-collect, more comfortable and preferred to standard combined nose and throat swabs, highly sensitive and accurate for SARS-CoV-2 detection, and more sensitive and has better COVID-19 case detection than saliva sampling. The trial confirms Rhinoswab Junior is the preferred method of sample collection for respiratory diseases for children whether for PCR or Rapid Antigen testing. Rhinoswab Junior has the potential to improve testing rates for a range of respiratory viruses at home, in schools and in a variety of health settings. Its unique design delivers a standardized sampling methodology for the first time. Rhinoswab Junior is listed for sale as a Class 1 device in Europe (CE Mark), in the USA (FDA), in the UK (MHRA), and in Australia (TGA).

“With SARS-CoV-2 variants and seasonal respiratory viruses continuing to evolve, and Europe heading into winter, we see a clear and compelling need for better testing and better case detection. Reducing the barriers to getting more people tested is crucial. Children remain a critical at risk population and we believe that the Rhinsowab Junior can radically improve testing uptake,” said Rhinomed CEO Michael Johnson. “Rhinomed is proud to have developed a swab that not only works better but removes anxiety and distress – not just for kids, but for their parents and health care workers. Even adults prefer Rhinoswab. We are excited to offer the demonstrated benefits of Rhinoswab Junior to the European market.”

Related Links:
Rhinomed Limited

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Protein ‘signatures’ obtained via a blood sample can be used to predict the onset of 67 diseases (Photo courtesy of Queen Mary University of London)

Protein Signatures in Blood Can Predict Risk of Developing More Than 60 Diseases

Measuring specific proteins to diagnose conditions like heart attacks, where troponin is tested, is a well-established clinical practice. Now, new research highlights the broader potential of protein measurements... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Microbiology

view channel
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically... Read more

Pathology

view channel
Image: The tool can improve precision oncology by accurately predicting molecular subtypes and therapy responses (Photo courtesy of Shutterstock)

Computational Tool Integrates Transcriptomic Data for Improved Breast Cancer Diagnosis and Treatment

Breast cancer is the most commonly diagnosed cancer globally, presenting in various subtypes that require precise identification for effective, personalized treatment. Traditionally, cancer subtyping has... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.